CAPS Medical develops the PlasmaSure™ system, which utilizes non-thermal atmospheric plasma delivered through a disposable catheter for the selective treatment of solid tumors. This minimally invasive approach targets cancer cells while preserving surrounding healthy tissue, addressing the challenges of traditional cancer therapies that often result in collateral damage.
Funding
$9.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer therapies often result in collateral damage to healthy tissue surrounding the tumor. This lack of selectivity can lead to significant side effects and complications, impacting patient prognosis and quality of life.
Solution
CAPS Medical develops the PlasmaSure™ system, a minimally invasive solution for the selective treatment of solid tumors. The system utilizes non-thermal atmospheric plasma delivered through a disposable catheter, allowing precise targeting of cancer cells while preserving surrounding healthy tissue. This approach overcomes the challenges of delivering non-thermal plasma to internal organs, offering a safer and more controlled treatment option. Real-time energy monitoring ensures consistent treatment delivery.
Target Audience
The primary target audience includes oncologists and hospitals treating patients with solid tumors, specifically lung, liver, breast, gastrointestinal, bladder, and prostate cancers.
Features
- Non-thermal atmospheric plasma technology for selective cancer cell destruction
- Minimally invasive procedure using a disposable catheter
- Precise tumor targeting to minimize damage to surrounding healthy tissue
- Real-time energy monitoring for consistent treatment delivery
- Keyhole procedure delivered through the working channel of standard minimally invasive tools
- No tissue incision, resulting in reduced bleeding and scarring